Format

Send to

Choose Destination
Antivir Ther. 2019 Mar 26. doi: 10.3851/IMP3307. [Epub ahead of print]

Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients.

Author information

1
Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain.
2
Department of Internal Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
3
Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
4
Hematology Service and Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.

Abstract

Cytomegalovirus (CMV) infections can induce severe complications in immunosuppressed patients. Currently, ganciclovir represents the preferred treatment option; however, in patients with resistance or toxicity related to ganciclovir, the therapeutic options are limited.Cellular immunity plays an important role in the control of viral infections. Adoptive T-cell therapy can contribute to recovering immunological function in immunosuppressed patients. Selective T-cell depletion targeting CD45RA enhances early T-cell recovery and can represent a salvage therapy. In this study, an immunocompromised non-transplanted patient with CMV disease and toxicity to conventional therapy was successfully treated by adoptive transfer of CD45RA-depleted T-cells.

PMID:
30912764
DOI:
10.3851/IMP3307

Supplemental Content

Loading ...
Support Center